Medtronic Heart Valve Gains FDA Clearance
Medtronic Inc. (NYSE: MDT) has announced the final follow-up results from its CoreValveĀ® CE Pivotal Study, which looks to be good news for heart patients. In a press release, Medtronic said the CoreValve System demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who … Read More